FSTX News
Archived Headlines
- US IPO Weekly Recap: Two healthcare companies price amid an improving market backdrop 03/18/16
- Spring Bank Pharma postpones $40 million IPO 03/18/16
- Week ahead: IPO calendar fills up 03/11/16
- A Hep B therapy: Spring Bank Pharmaceuticals sets terms for $40 million IPO 03/09/16
- US IPO Weekly Recap: 2016 IPO market kicks off with a flurry of biotech filings 01/08/16
See more
Spring Bank Pharma prices IPO at $12, the low end of the range
Spring Bank Pharmaceuticals, which is developing small molecule therapies for hepatitis B and viral diseases, raised $11 million by offering 0.9 million shares at $12, the low end of the range of $12 to $14. Spring Bank Pharmaceuticals plans to list on the...read more
US IPO Weekly Recap: Biotechs get pushback, but gene editing still soars
Of the four biotech IPOs that were scheduled to price this week, only two priced successfully. These were the first two biotech IPOs in almost a month, both of which had heavy insider buying. ...read more
Week ahead: Biotechs Strike Back with Four IPOs
After seven IPOs in a row outside the healthcare sector, four biotechs will attempt to price their IPOs in the week ahead, all with insider support. Looking more broadly, the next two weeks could see an increased number of launches if companies ...read more
Spring Bank Pharma slashes proposed deal size, relaunches IPO
Spring Bank Pharmaceuticals, which is developing small molecule therapies for hepatitis B and viral diseases, lowered the proposed deal size for its previously postponed IPO on Wednesday. The Hopkinton, MA-based company now plans to raise $15 million by...read more